Novel heterocyclic derivative with CDK (cyclin-dependent kinase) 4/6 and HDAC (histone deacetylase) inhibitory activities

The invention relates to a novel heterocyclic derivative having a formula (I) and salt. The novel heterocyclic derivative comprises pharmaceutical salt, wherein R1, R2, R3, R4, X, Z and L are defined in the text. Compounds of the novel heterocyclic derivative are a CDK (cyclin-dependent kinase) 4/6 inhibitor and an HDAC (histone deacetylase) inhibitor and can be used for treating diseases mediated by CDK4/6 and HDAC and disturbances, such as cancer including mantle cell lymphoma, liposarcomata, non-small cell lung cancer, melanomas, squamous cell esophagus cancer and breast cancer. The invention also relates to a pharmaceutical composition containing the compounds provided by the invention, and also relates to application of the compounds or pharmaceutical composition containing the compounds provided by the invention to treatment of related disturbances. .